<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02974699</url>
  </required_header>
  <id_info>
    <org_study_id>110116M1F</org_study_id>
    <nct_id>NCT02974699</nct_id>
  </id_info>
  <brief_title>Role of Gastrointestinal Microbes on Digestion of Resistant Starch and Tryptophan Availability to Humans</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wayne State University</source>
  <brief_summary>
    <textblock>
      There is currently a critical gap in knowledge of how intestinal bacterial communities alter&#xD;
      metabolic substrates available to the host thereby influencing central and enteric nervous&#xD;
      system (CNS/ENS) neurotransmitter levels involved in regulating carbohydrate consumption in&#xD;
      humans. Understanding these relationships is essential for developing strategies to improve&#xD;
      blood glucose control and to reduce the risk of transitioning from prediabetes to type-2&#xD;
      diabetes (T2D). The investigators' long-term goal is to determine the biological&#xD;
      underpinnings of behaviors that impact food intake and blood glucose control that contribute&#xD;
      to the development of T2D. The objective of this proposal, which is an essential next step in&#xD;
      attaining the investigators' long-term goals, is to determine how bacterial populations in&#xD;
      the digestive system impact circulating tryptophan (TRP) and large neutral amino acid (LNAA)&#xD;
      levels that regulate production of monoamine 5-hydroxytryptamine (5-HT, serotonin) in the ENS&#xD;
      and in gastrointestinal system and the brain. The central hypothesis is that a reduced ratio&#xD;
      of TRP producing (TRPp) to TRP consuming (TRPc) bacteria (decreased TRPp:TRPc ratio) in the&#xD;
      gut will decrease TRP availability following a carbohydrate meal lowering the plasma TRP:LNAA&#xD;
      ratio and resulting in less TRP for ENS/CNS production of 5HT. Further, dietary interventions&#xD;
      that promote TRPp bacterial abundance within the gut will increase TRP availability to the&#xD;
      host. The investigators will test the central hypothesis and, thereby, accomplish the overall&#xD;
      objective for this project by pursuing the following specific aims: 1) Assess impact of&#xD;
      divergent microbiota on plasma TRP:LNAA ratio in response to acute carbohydrate consumption,&#xD;
      and 2) Assess the impact of dietary supplementation with resistant starch (RS) on gut&#xD;
      microbiota and circulating TRP:LNAA ratio. During Aim 1, stool samples will be collected from&#xD;
      healthy participants. Participants will be stratified based on gut TRPp:TRPc ratio and the&#xD;
      response to an acute meal will be assessed by determining plasma TRP:LNAA ratios. During Aim&#xD;
      2 the capacity for 4-weeks of pre-biotic RS (Potato Starch) supplementation to increase the&#xD;
      TRPp:TRPc bacterial ratio in the gut will be determined from stool samples. Additionally,&#xD;
      plasma TRP:LNAA ratio following acute carbohydrate consumption before and after&#xD;
      supplementation will be determined. The scientific contribution will be to determine the&#xD;
      impact of RS on TRPp and TRPc bacteria abundance in the gut, and how bacterial populations&#xD;
      impact circulating TRP:LNAA levels, that can impact ENS and CNS 5HT production in humans.&#xD;
      This contribution will be significant because it will have direct translational implications&#xD;
      for human diseases with altered 5HT signaling.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2017</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Amino Acid Levels</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Amino Acid Levels</measure>
    <time_frame>Following 4 weeks of supplementation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Amino Acid Levels</measure>
    <time_frame>Baseline vs. 4-weeks</time_frame>
    <description>Difference in plasma amino acid levels between baseline and following 4-weeks of supplementation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type II Diabetes</condition>
  <arm_group>
    <arm_group_label>Potato Starch (Bob's Red Mill)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily dietary supplementation with Potato Starch (48g total/day) suspended in water. 24g will be consumed 2 times per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resource ThickenUp Pregelatinized Starch</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily dietary supplementation with Pregelatinized Starch (48g total/day) suspended in water. 24g will be consumed 2 times per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Potato Starch (Bob's Red Mill)</intervention_name>
    <description>Subjects will be assigned to Potato Starch (active) following assessment of their gut microbiome.</description>
    <arm_group_label>Potato Starch (Bob's Red Mill)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pregelatinized Starch (Resource ThickenUp)</intervention_name>
    <description>Subjects will be assigned to Pregelatinized Starch (placebo) following assessment of their gut microbiome.</description>
    <arm_group_label>Resource ThickenUp Pregelatinized Starch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female&#xD;
&#xD;
          2. Age 18 - 65 years old&#xD;
&#xD;
          3. Non-Obese (BMI â‰¤ 30 kg/m2 and &gt;17 kg/m2 )&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Urine toxicology positive,&#xD;
&#xD;
          2. Pregnant (female)&#xD;
&#xD;
          3. Alcohol intake 48 hours prior to studies,&#xD;
&#xD;
          4. Evidence of inherited disorders of lipid metabolism,&#xD;
&#xD;
          5. History of Cancer within the last 5 years,&#xD;
&#xD;
          6. Human immunodeficiency virus (HIV) antibody positive,&#xD;
&#xD;
          7. Patients with solid organ transplants,&#xD;
&#xD;
          8. Unstable angina or NY heart association class II failure or above,&#xD;
&#xD;
          9. Gastrointestinal disease specifically GI motility disorders,&#xD;
&#xD;
         10. Unstable neuropsychiatric disease including major depression/anxiety, eating disorder&#xD;
             such as bulimia or anorexia,&#xD;
&#xD;
         11. End stage renal or hepatic disease,&#xD;
&#xD;
         12. Autoimmune disorders (e.g. SLE),&#xD;
&#xD;
         13. Prior bariatric surgery,&#xD;
&#xD;
         14. A history or current alcohol/substance abuse or nicotine containing products or&#xD;
             illicit drugs of abuse during the preceding 6 months,&#xD;
&#xD;
         15. Treatment within one month with sedative hypnotic medications (benzodiazepines,&#xD;
             barbiturates), or over the counter sleeping aids&#xD;
&#xD;
         16. Women: any selective estrogen receptor modulator or aromatase inhibitor Men:&#xD;
&#xD;
             androgen ablation/deprivation hormonal therapies&#xD;
&#xD;
         17. Any medical condition, which in the opinion of the investigator would make the patient&#xD;
             unsuitable for recruitment, or could interfere with the patient participating in or&#xD;
             completing the protocol&#xD;
&#xD;
         18. Any previous adverse events or allergic reactions to acetaminophen&#xD;
&#xD;
         19. Unwilling or unable to consent for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paul R Burghardt, PhD</last_name>
    <phone>3135770107</phone>
    <email>paul.burghardt@wayne.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katlin Chappelle, BS</last_name>
    <phone>3135772716</phone>
    <email>fx3603@wayne.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Burghardt</last_name>
      <phone>313-577-0107</phone>
      <email>paul.burghardt@wayne.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>November 21, 2016</study_first_submitted>
  <study_first_submitted_qc>November 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2016</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wayne State University</investigator_affiliation>
    <investigator_full_name>Paul Burghardt</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

